PURE Bioscience, Inc. PURE
OTC PK
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -83.73% | -7.59% | 1.63% | 32.66% | 56.08% |
| Total Depreciation and Amortization | -- | -100.00% | 0.00% | -- | -100.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 66.67% | 66.67% | 114.81% | -40.35% | -21.05% |
| Change in Net Operating Assets | 194.16% | 197.06% | -46.90% | 38.76% | -277.01% |
| Cash from Operations | 9.21% | 8.59% | -11.40% | 50.30% | 23.10% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -100.00% | -70.59% | -7.50% | -30.00% | -50.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.00% | 47.41% | -7.50% | -30.00% | -50.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -100.97% | 132.25% | -63.89% | 3,433.33% | -121.51% |